Skip to Content
image description
  • image description
  • image description
  • image description

Studies List

To request more information about a specific clinical trial/study, complete our contact form.

Cardiology and Diabetes

CAMELLIA

Study to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCI) on incidence of major adverse CV events and conversion to type 2 DM in obese/overweight subjects with CV disease or multiple CV risk factors.

Principal Investigator: Ricky Schneider, MD
Contact: 954-346-0864
Coral Springs, FL

Cardiology and Diabetes

THEMIS

The effect of Ticagrelor 90 mg twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes mellitus.

Principal Investigator: Ricky Schneider, MD
Contact: 954-346-0864
Coral Springs, FL

Cardiology and Diabetes

DECLARE-TIMI 58

A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of dapagliflozin 10 mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes. Dapagliflozin is an investigational drug that is part of a new class of drugs for diabetes. Dapagliflozin works by causing the kidneys to remove excess sugar (glucose) in the urine, which in turn helps lower the amount of sugar (glucose) in the blood.  Dapagliflozin does this without the involvement of insulin.  Studies have shown dapagliflozin to be effective in lowering glucose levels in the blood and in addition, in lowering body weight and blood pressure.  It is thought that by better controlling the levels of glucose in the blood and by lowering body weight and blood pressure, dapagliflozin may reduce the risk of cardiovascular events, including heart attacks.

Principal Investigator: Ricky Schneider, MD
Contact: 954-346-0864
Coral Springs, FL

Cardiology and Diabetes

EXSCEL

This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular combined endpoint of cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke - in patients with type 2 diabetes mellitus.

Principal Investigator: Novelette Thompson, MD
Contact: 954-229-8400
Fort Lauderdale, FL

Electrophysiology

ORBIT-AF II

Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation is designed to evaluate the utilization of target-specific antithrombotic agents, such as factor Xa (FXa) inhibitors and direct thrombin inhibitors, and associated outcomes.

Principal Investigator: Ricky Schneider, MD
Contact: 954-346-0864
Coral Springs, FL

Electrophysiology

Analyze ST

AnalyST and Brugada Syndrome Feasibility Study - ST monitoring to detect ACS events in ICD patients study.

Principal Investigator: Rishi Anand, MD, FHRS
Contact: 954-229-8400
Fort Lauderdale, FL

General Cardiology

BRIDGE

A Phase III study for bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery.

Principal Investigator: Charles Russo, MD, FACC
Contact: 954-229-8400
Fort Lauderdale, FL

General Cardiology

Fourier

Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk.

Principal Investigator: Karan Munuswamy, MD
Contact: 954-229-8400
Fort Lauderdale, FL

General Cardiology

COMPASS

The main purpose of this study is to test whether a drug called rivaroxaban, given alone or together with aspirin, is more effective than aspirin alone in preventing heart attacks and strokes in people with hardening of the arteries (“atherosclerosis”) involving the arteries of the heart muscle, legs, or brain. Both aspirin and rivaroxaban can cause bleeding from the lining of the stomach and small intestine. A second purpose of this study is to test whether a drug called pantoprazole (also referred to as a proton pump inhibitor or “PPI”) will prevent bleeding from the stomach and intestine when taken with rivaroxaban and aspirin.  The U.S. Food and Drug Administration (FDA) has approved pantoprazole for use to treat bleeding from the lining of the stomach and small intestine. This study will test an investigational use of pantoprazole. An “investigational use” is a use that is being tested and is not approved by the FDA.

Principal Investigator: Ricky Schneider, MD
Contact: 954-346-0864
Coral Springs, FL

General Cardiology

Odyssey Outcomes

Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with Alirocumab SAR236553 (REGN727). The primary objective of this study is to compare the effect of SAR236553 with placebo on the occurrence of cardiovascular events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) in patients who have experienced an acute coronary syndrome (ACS) event 4 to 16 weeks prior to randomization and are treated with intensive statin therapy (defined as atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg) or at maximally tolerated dose of these given statins, or other non statin LMT(s).

Principal Investigator: Joshua Purow, MD, FACC
Contact: 954-229-8400
Fort Lauderdale, FL

Heart Failure

ARTS-HF

Phase IIb safety and efficacy study of different oral doses of BAY94-8862 in subjects with worsening chronic heart failure and left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or chonic kidney disease alone.

Principal Investigator: Joshua Larned, MD, FACC
Contact: 954-229-8400
Fort Lauderdale, FL

Heart Failure

BAY 1021189 / 15371 SOCRATES - REDUCED

Phase IIb safety and efficacy study of four dose regimens of BAY1021189 in patients with heart failure with reduced ejection fraction suffering from worsening chronic heart failure.

Principal Investigator: Joshua Larned, MD, FACC
Contact: 954-229-8400
Fort Lauderdale, FL

Heart Failure

BAY 1021189 / 15829 SOCRATES - PRESERVED

Phase IIb safety and efficacy study of four dose regimens of BAY1021189 in patients with heart failure and preserved ejection fraction suffering from worsening chronic heart failure.

Principal Investigator: Joshua Larned, MD, FACC
Contact: 954-229-8400
Fort Lauderdale, FL

Heart Failure

GUIDE-IT

Guiding evidence based therapy using biomarker intensified treatment - comparing achieving and maintaining an NT-proBNP target of <1000pg/ml to usual care in high risk patients with systolic heart failure.

Principal Investigator: Joshua Larned, MD, FACC
Contact: 954-229-8400
Fort Lauderdale, FL

Principal Investigator: Ricky Schneider, MD
Contact: 954-346-0864
Coral Springs, FL

Humanitarian Use Devices

HUD-Wingspan

WingspanTM Stent System with GatewayTM PTA Balloon Catheter - The Wingspan Stent System and Gateway PTA Balloon Catheter is authorized by Federal law for use in improving cerebral artery lumen diameter in patients with intracranial atherosclerotic disease, refractory to medical therapy, in intracranial vessels with >50% stenosis that are accessible to the system.

Principal Investigator: Laszlo Miskolczi, MD
Contact: 954-229-8400
Fort Lauderdale, FL

Pages

Human Heart

Holy Cross Hospital is committed to cutting-edge heart research and to offering the most advanced cardiac care in South Florida. Meet our team of principal investigators who are dedicated to providing the best cardiac care in our community.

Request Info

Clinical Trial Info

Directions

image description

Studies

man getting heart procedure